---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-128517"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-12-13T23:59:59+00:00"
generated_at: "2026-05-29T03:20:03.288961+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Path receives Nasdaq bid-price deficiency notice; shareholders OK reverse split

## Summary
- Nasdaq letter Dec 12, 2024: closing bid below $1 for 30 straight days; 180 days until June 10, 2025 to comply.
- Stockholders approved reverse stock split up to 1-for-30 to potentially cure deficiency.
- Approved increase in 2022 Stock Incentive Plan shares by 1,200,000 to total 1,265,000 shares.
- Ratified Ernst & Young as independent auditor for fiscal year ending Dec 31, 2024.
- All five director nominees elected with over 80% of votes cast for each.

## SEC filing metadata
- accession: 0001104659-24-128517
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000110465924128517/0001104659-24-128517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000110465924128517/tm2431094d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-128517
- JSON: https://secwatch.observer/filing/0001104659-24-128517.json
- Plain text: https://secwatch.observer/filing/0001104659-24-128517.txt

## Key facts
- Listing & Compliance Notices
  BIO-PATH HOLDINGS, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: December 12, 2024, Bio-Path Holdings, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar day
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133818/000110465924128517/0001104659-24-128517-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.